Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up

Departement de Cardiologie, Hopital Universitaire Saint-Jacques, Besancon, France.

OBJECTIVES: This study sought to compare the efficacy of 2-h regimens of alteplase and streptokinase in acute massive pulmonary embolism. The primary end point was immediate hemodynamic improvement, and secondary end points included early clinical efficacy and safety, as well as 1-year clinical outcome. BACKGROUND: Several thrombolytic regimens have been compared for the past 10 years in randomized studies, showing that 2-h infusion regimens of alteplase or urokinase lead to faster hemodynamic improvement than former 12- to 24-h administration protocols in acute massive pulmonary embolism. Many trials have focused on immediate hemodynamic and angiographic outcomes, but none has addressed long-term follow-up after thrombolysis. METHODS: Sixty-six patients with acute massive pulmonary embolism (Miller score > 17 and mean pulmonary artery pressure >20 mm Hg) were randomly assigned to receive either a 100-mg 2-h infusion of alteplase (n = 23) or 1.5 million IU of streptokinase over 2 h (n = 43). In both groups, heparin infusion was started at the end of thrombolytic infusion and adapted thereafter. Total pulmonary resistance was monitored over a 12-h period. Pulmonary vascular obstruction was assessed 36 to 48 h after thrombolytic therapy. One-year follow-up information included death, cause of death, recurrent pulmonary embolism, chronic thromboembolic pulmonary hypertension, stroke and bleeding. RESULTS: Both groups had similar baseline angiographic and hemodynamic characteristics of severity, with maintained cardiac output in 64 (97%) of 66 patients. The results (mean +/- SD) demonstrated that despite a faster total pulmonary resistance improvement observed at 1 h in the alteplase group compared with the streptokinase group (33+/-16% vs. 19 16%, p = 0.006), a similar hemodynamic efficacy was obtained at 2 h when both thrombolytic regimens were completed (38+/-18% vs. 31+/-19%). There was no significant difference in either pulmonary vascular obstruction at 36 to 48 h or bleeding complication rates. One-year event-free survival was similar in both groups, as most events were related to concomitant diseases. CONCLUSIONS: These results suggest that a 2-h regimen of streptokinase can be routinely used in patients with massive pulmonary embolism and maintained cardiac output without obviously compromising efficacy or safety.

This article has been cited by other articles:

				C. Kearon, E. A. Akl, A. J. Comerota, P. Prandoni, H. Bounameaux, S. Z. Goldhaber, M. E. Nelson, P. S. Wells, M. K. Gould, F. Dentali, et al. Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest, February 1, 2012; 141(2_suppl): e419S - e494S. [Abstract] [Full Text] [PDF]

				P. S. Marshall, K. S. Mathews, and M. D. Siegel Diagnosis and Management of Life-Threatening Pulmonary Embolism J Intensive Care Med, October 1, 2011; 26(5): 275 - 294. [Abstract] [PDF]

				C. Wang, Z. Zhai, Y. Yang, Q. Wu, Z. Cheng, L. Liang, H. Dai, K. Huang, W. Lu, Z. Zhang, et al. Efficacy and Safety of Low Dose Recombinant Tissue-Type Plasminogen Activator for the Treatment of Acute Pulmonary Thromboembolism: A Randomized, Multicenter, Controlled Trial Chest, February 1, 2010; 137(2): 254 - 262. [Abstract] [Full Text] [PDF]

				Authors/Task Force Members, A. Torbicki, A. Perrier, S. Konstantinides, G. Agnelli, N. Galie, P. Pruszczyk, F. Bengel, A. J.B. Brady, D. Ferreira, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur. Heart J., September 2, 2008; 29(18): 2276 - 2315. [Full Text] [PDF]

				C. Kearon, S. R. Kahn, G. Agnelli, S. Goldhaber, G. E. Raskob, and A. J. Comerota Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 454S - 545S. [Abstract] [Full Text] [PDF]

				T. Capstick and M. T. Henry Efficacy of thrombolytic agents in the treatment of pulmonary embolism Eur. Respir. J., November 1, 2005; 26(5): 864 - 874. [Abstract] [Full Text] [PDF]

				T Harris and S Meek When should we thrombolyse patients with pulmonary embolism? A systematic review of the literature Emerg. Med. J., November 1, 2005; 22(11): 766 - 771. [Abstract] [Full Text] [PDF]

				E. Ferrari, M. Benhamou, F. Berthier, and M. Baudouy Mobile Thrombi of the Right Heart in Pulmonary Embolism: Delayed Disappearance After Thrombolytic Treatment Chest, March 1, 2005; 127(3): 1051 - 1053. [Abstract] [Full Text] [PDF]

				J. W. Kreit The Impact of Right Ventricular Dysfunction on the Prognosis and Therapy of Normotensive Patients With Pulmonary Embolism Chest, April 1, 2004; 125(4): 1539 - 1545. [Abstract] [Full Text] [PDF]

				N. Meneveau, L. P. Ming, M. F. Seronde, N. Mersin, F. Schiele, F. Caulfield, Y. Bernard, and J.-P. Bassand In-hospital and long-term outcome after sub-massive and massive pulmonary embolism submitted to thrombolytic therapy Eur. Heart J., August 1, 2003; 24(15): 1447 - 1454. [Abstract] [Full Text] [PDF]

				British Thoracic Society guidelines for the management of suspected acute pulmonary embolism Thorax, June 1, 2003; 58(6): 470 - 483. [Full Text] [PDF]

				K McNeil, J Dunning, and N W Morrell The pulmonary physician in critical care * 13: The pulmonary circulation and right ventricular failure in the ITU Thorax, February 1, 2003; 58(2): 157 - 162. [Abstract] [Full Text] [PDF]

				G. Thabut, D. Thabut, R. P. Myers, B. Bernard-Chabert, R. Marrash-Chahla, H. Mal, and M. Fournier Thrombolytic therapy of pulmonary embolism: A meta-analysis J. Am. Coll. Cardiol., November 6, 2002; 40(9): 1660 - 1667. [Abstract] [Full Text] [PDF]

				W. F. Baker Jr Thrombolytic Therapy Clinical and Applied Thrombosis/Hemostasis, October 1, 2002; 8(4): 291 - 314. [PDF]

				M. Podbregar, B. Krivec, and G. Voga Impact of Morphologic Characteristics of Central Pulmonary Thromboemboli in Massive Pulmonary Embolism* Chest, September 1, 2002; 122(3): 973 - 979. [Abstract] [Full Text] [PDF]

				K. E. Wood Major Pulmonary Embolism : Review of a Pathophysiologic Approach to the Golden Hour of Hemodynamically Significant Pulmonary Embolism Chest, March 1, 2002; 121(3): 877 - 905. [Abstract] [Full Text] [PDF]

				C K Pager Streptokinase versus alteplase and other treatments for acute and delayed thrombolysis of blood stains in clothing BMJ, December 23, 2000; 321(7276): 1554 - 1556. [Abstract] [Full Text]

				M.D. Thomas, A. Chauhan, and R.S. More Pulmonary embolism--an update on thrombolytic therapy QJM, May 1, 2000; 93(5): 261 - 267. [Full Text] [PDF]

				W.-K. Chan and T.-F. Chan Thrombolysis for acute pulmonary embolism in Chinese patients QJM, February 1, 2000; 93(2): 125 - 127. [Full Text] [PDF]

				S. M. Arcasoy and J. W. Kreit Thrombolytic Therapy of Pulmonary Embolism: A Comprehensive Review of Current Evidence Chest, June 1, 1999; 115(6): 1695 - 1707. [Abstract] [Full Text] [PDF]

				Which Thrombolytic Is Best in PE? Journal Watch Emergency Medicine, June 1, 1998; 1998(601): 3 - 3. [Full Text]